Literature DB >> 12644588

Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

William F Hood1, James K Gierse, Peter C Isakson, James R Kiefer, Ravi G Kurumbail, Karen Seibert, Joseph B Monahan.   

Abstract

Two compounds (celecoxib and valdecoxib) from the diarylheterocycle class of cyclooxygenase inhibitors were radiolabeled and used to characterize their binding to cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), several single-point variants of COX-2 (Val523Ile, Tyr355Ala, Arg120Ala, Arg120Gln, Arg120Asn) and one triple-point variant of COX-2 [Val523Ile, Arg513His, Val434Ile (IHI)]. We demonstrate highly specific and saturable binding of these inhibitors to COX-2. Under the same assay conditions, little or no specific binding to COX-1 could be detected. The affinity of [(3)H]celecoxib for COX-2 (K(D) = 2.3 nM) was similar to the affinity of [(3)H]valdecoxib (K(D) = 3.2 nM). The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 x 10(6)/M/min and 4.5 x 10(6)/M/min and dissociation rates of 14 x 10(-3)/min (t(1/2) = 50 min) and 7.0 x 10(-3)/min (t(1/2) = 98 min) for [(3)H]celecoxib and [(3)H]valdecoxib, respectively. These association rates increased (4- to 11-fold) when the charged arginine residue located at the entrance to the main hydrophobic channel was mutated to smaller uncharged amino acids (Arg120Ala, Arg120Gln, and Arg120Asn). Mutation of residues located within the active site of COX-2 that define a 'side pocket' (Tyr355Ala, Val523Ile, IHI) of the main channel had a greater effect on the dissociation rate than the association rate. These mutations, which modified the shape of and access to the 'side pocket', affected the binding affinity of [(3)H]valdecoxib more than that of [(3)H]celecoxib. These binding studies provide direct insight into the properties and binding constants of celecoxib and valdecoxib to COX-2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644588     DOI: 10.1124/mol.63.4.870

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  COX2 inhibition reduces aortic valve calcification in vivo.

Authors:  Elaine E Wirrig; M Victoria Gomez; Robert B Hinton; Katherine E Yutzey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-26       Impact factor: 8.311

2.  An Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells.

Authors:  Anuj K Yadav; Christopher J Reinhardt; Andres S Arango; Hannah C Huff; Liang Dong; Michael G Malkowski; Aditi Das; Emad Tajkhorshid; Jefferson Chan
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-06       Impact factor: 15.336

3.  Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.

Authors:  Fatma M Abdallah; Maged W Helmy; Mohamed A Katary; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-28       Impact factor: 3.000

4.  Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.

Authors:  Richard L Julius; Omar K Farha; Janet Chiang; L Jeanne Perry; M Frederick Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-13       Impact factor: 11.205

5.  The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs.

Authors:  Heiko Neuss; Xiaohua Huang; Bettina K J Hetfeld; Rupal Deva; Petra Henklein; Santosh Nigam; Julian W Mall; Wolfgang Schwenk; Wolfgang Dubiel
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

6.  Cancer-linked targets modulated by curcumin.

Authors:  Noor Hasima; Bharat B Aggarwal
Journal:  Int J Biochem Mol Biol       Date:  2012-12-24

7.  Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).

Authors:  M Gallicchio; A C Rosa; C Dianzani; L Brucato; E Benetti; M Collino; R Fantozzi
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

Review 8.  Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.

Authors:  Caroline Fenton; Gillian M Keating; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.

Authors:  Shahar Lev-Ari; Dina Kazanov; Eliezer Liberman; Rami Ben-Yosef; Nadir Arber
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

10.  Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue.

Authors:  Stefan Saretz; Gabriele Basset; Liridona Useini; Markus Laube; Jens Pietzsch; Dijana Drača; Danijela Maksimović-Ivanić; Johannes Trambauer; Harald Steiner; Evamarie Hey-Hawkins
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.